The relationship between carboplatin AUC and serum thrombopoietin kinetics in patients with lung cancer

Anticancer Research

Volumn 19, Issue 1 B, 1999, Pages 667-670

  Miyazaki, Mitsuru ^a   Fujiwara, Yasuhiro ^a,c   Isobe, Takeshi ^a   Yamakido, Michio ^a   Kato, Takashi ^b   Miyazaki, Hiroshi ^b  

^a HIROSHIMA UNIV SCHOOL OF MEDICINE   (Japan)

^b KIRIN BREWERY CO LTD   (Japan)

^c NATIONAL INSTITUTE OF HEALTH SCIENCES   (Japan)

Author keywords

Carboplatin; Lung cancer; Pharmacokinetics; Thrombocytopenia; Thrombproietin

Indexed keywords

CARBOPLATIN; THROMBOPOIETIN;

ADULT; AGED; AREA UNDER THE CURVE; ARTICLE; CLINICAL ARTICLE; CLINICAL TRIAL; DOSE TIME EFFECT RELATION; FEMALE; HUMAN; INTRAVENOUS DRUG ADMINISTRATION; LUNG CANCER; LUNG NON SMALL CELL CANCER; MALE; PRIORITY JOURNAL; THROMBOCYTE COUNT; THROMBOCYTOPENIA;

ADENOCARCINOMA; AGED; AREA UNDER CURVE; CARBOPLATIN; CARCINOMA, NON-SMALL-CELL LUNG; CARCINOMA, SQUAMOUS CELL; FEMALE; HUMANS; LUNG NEOPLASMS; MALE; MIDDLE AGED; PLATELET COUNT; THROMBOPOIETIN; TIME FACTORS;

EID: 0032945856     PISSN: 02507005     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (11)

1. Fanucchi M, Glaspy J, Crawford J, Garst J, Figlin R, Sheridan W, Menchaca D, Tomita D, Ozer H, Harker L: Effects of polyethylene glycol-conjugated recombinant human megakaryocyte growth and development factor on platelet counts after chemotherapy for lung cancer. N Engl J Med 336: 404-409, 1997.
2. Egorin MJ, Van Echo DA, Tipping SJ, Olman EA, Whitacre MY, Thompson BW, Aisner J: Pharmacokinetics and dosage reduction of cis-diammine (1,1-cyclobutanedicarboxylato) platinum in patients with impaired renal function. Cancer Res 44: 5432-5438, 1984.
3. Calvert AH, Newell DR, Gumbrell LA, O'Reilly S, Burnell M, Boxall FE, Siddik ZH, Judson IR, Gore ME, Alilshaw E:Carboplatin dosage: prospective evaluation of a simple formula based on renal function. J Clin Oncol 7: 1748-1756, 1989.
4. Fujiwara Y, Takahashi T, Yamakido M, Ohune T, Tsuya T, Egorin MJ: Re: Prediction of carboplatin clearance from standard morphological and biological patient characteristics. J Natl Cancer Inst 89: 260-262, 1997.
5. D'Argenio DZ, Scumitzky A: A program package for simulation and parameter estimation in pharmacokinetic systems. Comput Prog Biomed 9: 115-134, 1979.
6. Tahara T, Usuki K, Sato H, Ohashi H, Morita H, Tsumura H, Matsumoto A, Miyazaki H, Urabe A, Kato T: A sensitive sandwich ELISA for measuring thrombopoietin in human serum: Serum thrombopoietin levels in healthy volunteers and in patients with haemopoietic disorders. Br J Haematol 93: 783-788, 1996.
7. Kuter DJ, Beeler DL, Rosenberg RD: The purification of megapoietin: A physiological regulator of megakaryocyte growth and platelet production. Proc Natl Acad Sci USA 91: 11104-11108, 1994.
8. Emmons RVB, Reid DM, Cohen RL, Meng G, Young NS, Dunhar CE. Shulman NR: Human thrombopoietin levels are high when thrombocytopenia is due to megakaryocyte deficiency and low when due to increased platelet destruction. Blood 87: 4068-4071, 1996.
9. Basser RL, Rasko JEJ, Clarke K, Cebon J, Green MD, Hussein S, Alt C, Menchaca D, Tomita D, Marty J, Fox RM, Begley CG: Thrombopoietic effects of pegylated recombinant human megakaryocyte growth and development factor (PEG-rHuMGDF) in patients with advanced cancer. Lancet 348: 1279-1281, 1996.
10. Vadhan-Raj S, Murray LJ, Bueso-Ramos C, Patel S, Reddy SP, Hoots WK, Johnston T, Papadopolous NE, Hittelman WN, Johnston DA, Yang TA, Paton VE, Cohen RL, Hellmann SD, Benjamin RS, Broxmeyer HE: Stimulation of megakaryocyte and platelet production by a single dose of recombinant human thrombopoietin in patients with cancer. Annals of Internal Medicine 126: 673-681, 1997.
11. Akahori H, Ozai M, Ida M, Shibuya K, Kato T, Miyazaki H: Further examination of various administration protocols of pegylated recombinant human megakaryocyte growth and development factor on thrombocytopenia, in myelosuppressed mice. Therapeutic Apheresis 2: 58-64, 1998.